Sutro Biopharma, Inc. (STRO) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Sutro Biopharma, Inc. is a clinical-stage oncology company developing site-specific antibody drug conjugates (ADCs) using its proprietary XpressCF and XpressCF+ platforms. The company has no products approved for commercial sale. This report covers the quarterly period ended September 30, 2024. As of November 7, 2024, the company had 82,458,725 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $8.5 million | $16.9 million | $47.2 million | $40.0 million |
| Net Loss | $(48.8) million | $(49.3) million | $(155.0) million | $(137.9) million |
| Loss Per Share (Basic/Diluted) | $(0.59) | $(0.81) | $(2.07) | $(2.30) |
| Operating Expenses | $76.4 million | $60.9 million | $220.4 million | $172.4 million |
| Cash & Cash Equivalents | $174.6 million | $69.3 million (Dec 2023) | - | - |
| Marketable Securities | $213.7 million | $264.4 million (Dec 2023) | - | - |
| Total Liquidity (Cash + Securities) | $388.3 million | $333.7 million (Dec 2023) | - | - |
| Accumulated Deficit | $(714.4) million | $(559.4) million (Dec 2023) | - | - |
Note: Revenue is derived primarily from collaboration and license agreements. The company reported a realized gain of $32.1 million on the sale of Vaxcyte common stock during the nine months ended September 30, 2024, which reduced the net loss.
Material Changes vs. Prior Period
- Revenue Decline (Q3): Revenue decreased 50% year-over-year to $8.5 million, primarily due to the absence of a $5.0 million contingent payment from Tasly recognized in Q3 2023 and a decrease in revenue from Astellas.
- Revenue Increase (9M): Revenue increased 18% year-over-year to $47.2 million, driven by a $20.2 million increase from Astellas (including a $17.8 million cumulative catch-up adjustment due to contract modification) and new revenue from Ipsen.
- Expense Growth: Research and Development (R&D) expenses increased 36% in Q3 and 43% in the nine-month period, driven by increased external services (CMO activities), clinical development, and personnel costs.
- Non-Cash Interest Expense: Non-cash interest expense related to the sale of future royalties increased significantly to $7.9 million in Q3 (from $5.9 million in Q3 2023) and $22.4 million for the nine months (from $6.4 million in 2023).
- Liquidity Position: Total cash, cash equivalents, and marketable securities increased to $388.3 million from $333.7 million at year-end 2023, bolstered by an underwritten offering and proceeds from the Ipsen agreement.
Guidance, Outlook, and Management Commentary
- Liquidity Outlook: Management believes current resources ($388.3 million) will fund operations for at least the next 12 months. However, the company expects to continue incurring substantial losses and will need to raise additional capital to support R&D and operations.
- Capital Raising: In April 2024, the company completed an underwritten offering raising approximately $75.0 million gross. In March 2024, an agreement with Ipsen included a $50.0 million upfront payment and a $25.0 million stock purchase.
- Key Developments:
- Luvelta (STRO-002): Enrollment for Part 1 of the Phase 2/3 REFRaME-O1 study for platinum-resistant ovarian cancer was completed in April 2024, with Part 2 initiated. A Phase 2 study for non-small cell lung cancer (NSCLC) began in August 2024.
- Collaborations: Astellas notified the company it would not nominate a third target program, resulting in a contract modification and revenue adjustment. Merck discontinued the clinical trial of MK-1484 in August 2024.
- Asset Sales: The company sold all remaining shares of Vaxcyte common stock in Q3 2024 for net proceeds of $74.0 million.
- Risks: Significant risks include the failure of product candidates in clinical trials, inability to secure additional funding, dependence on collaborators, and the complexity of manufacturing cell-free products.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $388.3 million liquidity position against the current quarterly net cash used in operating activities (~$40 million run rate implied by 9M data).
- Revenue Recognition: Review the details of the $17.8 million cumulative catch-up adjustment from Astellas to understand the remaining deferred revenue and future recognition timeline.
- Deferred Royalty Obligation: Monitor the growth of the $172.0 million deferred royalty liability related to the Blackstone sale of future royalties, which accrues non-cash interest expense.
- Clinical Milestones: Track the progress of the REFRaME-O1 study for luvelta and the initiation of the NSCLC Phase 2 study as key value drivers.
- Collaborator Dependence: Assess the impact of recent partner decisions (Astellas dropping a target, Merck discontinuing a trial) on future revenue streams and R&D strategy.